Title Profilaktička terapija migrenskih glavobolja Title (english) Prophylactic therapy of migraine headaches Author Erna Šarić Mentor Darija Mahović Lakušić (mentor)Committee member Branko Malojčić (predsjednik povjerenstva)Committee member Mario Habek (član povjerenstva)Committee member Darija Mahović Lakušić (član povjerenstva)Granter University of Zagreb Defense date and country 2024-09-11, Croatia Scientific / art field, BIOMEDICINE AND HEALTHCARE Abstract Migrena je neurološka bolest koja se manifestira jakom, pulsirajućom boli u trajanju od 4 do 72 sata, često popraćenom simptomima poput mučnine, povraćanja, fotofobije i fonofobije. Prema globalnom istraživanju opterećenosti bolestima, migrena je drugi najčešći neurološki poremećaj na svijetu s većom prevalencijom kod žena i uzrokuje veću invalidnost nego svi drugi neurološki poremećaji zajedno. Točan uzrok migrene nije poznat, no smatra se da je kompleksnost ove bolesti posljedica interakcije genetskih i okolišnih čimbenika, stila života i navika, te združenog pretjeranog odgovora aktivacije neuroloških i vaskularnih struktura na pojedine čimbenike. Prema današnjim saznanjima, ključ u patofiziologiji migrene je aktivacija trigeminovaskularnog sustava i lučenje CGRP peptida s posljedičnom neurogenom inflamacijom i dilatacijom intrakranijskih krvnih žila. Dijagnoza migrene postavlja se na temelju kliničke slike i simptoma, te se sukladno kriterijima Medunarođnog društva za glavobolju (engl. International Headache Society) svrstava u odgovarajuću klasifikaciju. Prema prepoukama Europske federacije neuroloških društava (engl. European Federation of Neurological Societies), terapija je usmjerena na abortivno i profilaktičko liječenje. Profilaktička terapija podijeljena je na farmakološke i nefarmakološke opcije, čijom se združenom primjenom može unaprijediti cjelokupni proces liječenja. Farmakološka terapija može se podijeliti na nespecifičnu u kojoj se primjenjuju lijekovi koji izvorno nisu razvijeni za liječenje migrene, ali su pokazali određenu razinu učinkovitosti, te specifičnu, u koju se ubrajaju CGRP antagonisti. Riječ je o skupini lijekova koja je posljednjih godina prošla kroz pravu revoluciju. Razvoj novih lijekova ciljanih za liječenje migrene pokazao je obećavajuće rezultate, kako u terapiji, tako i u sigurnosti primjene.
Abstract (english) Migraine is a neurological disease characterized by intense, pulsating pain lasting from 4 to 72 hours, often accompanied by symptoms such as nausea, vomiting, photophobia, and phonophobia. According to the Global Burden of Disease survey, migraine is the second most common neurological disorder in the world, with a higher prevalence in women, causing more disability than all other neurological disorders combined. The exact cause of migraine is unknown, but it is believed that the complexity of this disease results from the interaction of genetic and environmental factors, lifestyle and habits and the combined excessive response of neurological and vascular structures to certain triggers. Current knowledge suggests that the key to the pathophysiology of migraine lies in the activation of the trigeminovascular system and the release of CGRP peptide, leading to neurogenic inflammation and dilation of intracranial blood vessels.
Migraine is diagnosed based on clinical presentation and symptoms and is classified according to the criteria of the International Headache Society (IHS). According to the recommendations of the European Federation of Neurological Societies (EFNS), treatment is focused on both abortive and prophylactic management. Prophylactic therapy is divided into pharmacological and non-pharmacological options, with their combined use potentially enhancing the overall treatment process. Pharmacological therapy can be further divided into non-specific, where medications not originally developed for migraine treatment are used but have shown some efficacy, and specific, which includes CGRP antagonists. This group of drugs has undergone a significant revolution in recent years. The development of new drugs specifically targeted for migraine treatment has shown promising results in both efficacy and safety.
Keywords
migrena
CGRP
profilaktička terapija
monoklonska antitijela
gepanti
Keywords (english)
migraine
CGRP
prophylactic therapy
monoclonal antibodies
gepants
Language croatian URN:NBN urn:nbn:hr:105:328380 Study programme Title: Medicine Type of resource Text File origin Born digital Access conditions Open access Terms of use Created on 2024-09-09 14:52:28
